https://www.selleckchem.com/pr....oducts/anlotinib-al3
The primary efficacy outcome in these pivotal studies is change from baseline to end of treatment in the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS). Additional efficacy endpoints and safety/tolerability are also evaluated. ARTISTS is a 56-week, open-label, single-arm, long-term safety/tolerability study in patients who have successfully completed either ARTISTS 1 or ARTISTS 2. RESULTS Not available yet. CONCLUSION TS can have potentially long-term life impact, and there remains unmet medical need for ef
Like
Comment
Share
